The Patent Finder

ANTI-C5 Antibodies Having Improved Pharmacokinetics

Alexion Pharmaceuticals, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 9 of these applications claim priority to application 61/949,932, filed Mar 7, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 9,079,949ANTI-C5 Antibodies Having Improved Pharmacokinetics
In force
 · High confidence
UsedRemaining
Alexion Pharmaceuticals, Inc.In forceHigh confidence
US 9,107,861Methods of Treating C5 Mediated Complement-Associated Conditions with ANTI-C5 Antibodies Having Improved Pharmacokinetics
In force
 · High confidence
Alexion Pharmaceuticals, Inc.In forceHigh confidence
US 9,206,251Nucleic Acids Encoding ANTI-C5 Antibodies Having Improved Pharmacokinetics
In force
 · High confidence
Alexion Pharmaceuticals, Inc.In forceHigh confidence
US 9,371,377ANTI-C5 Antibodies Having Improved Pharmacokinetics
In force
 · Medium confidence
Alexion Pharmaceuticals, Inc.In forceMedium confidence
US 9,663,574ANTI-C5 Antibodies Having Improved Pharmacokinetics
In force
 · Medium confidence
Alexion Pharmaceuticals, Inc.In forceMedium confidence
US 9,803,007ANTI-C5 Antibodies Having Improved Pharmacokinetics
In force
 · Medium confidence
Alexion Pharmaceuticals, Inc.In forceMedium confidence
US 10,227,400Methods of Treating Atypical Hemolytic Uremic Syndrome with ANTI-C5 Antibodies
In force
 · Medium confidence
Alexion Pharmaceuticals, Inc.In forceMedium confidence
US 10,584,164Methods of Treating Atypical Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria with ANTI-C5 Antibodies
In force
 · Medium confidence
Alexion Pharmaceuticals, Inc.In forceMedium confidence
US 11,434,280ANTI-C5 Antibodies Having Improved Pharmacokinetics
In force
 · Medium confidence
Alexion Pharmaceuticals, Inc.In forceMedium confidence
Application 17/865,681ANTI-C5 Antibodies Having Improved Pharmacokinetics
Abandoned
Abandoned Jul 18, 2023
Alexion Pharmaceuticals, Inc.AbandonedAbandoned Jul 18, 2023
2 more records in this group · Pro
10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 12.
Upgrade to Pro
9 of these are in force and held by Alexion Pharmaceuticals, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited